Chronic kidney disease

Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients

Retrieved on: 
Thursday, March 28, 2024
CSL Vifor, Thrombosis, Myocardial infarction, Akebia, CKD, Patient, Tablet, Public, Stroke, Death, Therapy, Nephrology, Safety, Chronic kidney disease, Dialysis, Anemia, Division, Stanford University, Food, FDA, Pharmaceutical industry

Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia.

Key Points: 
  • Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia.
  • "As we continue to deliver on our promise for patients and public health, we are eager to closely collaborate with our partners to make this new oral treatment option available to patients."
  • Results from the INNO2VATE program were published in the New England Journal of Medicine: (N Engl J Med 2021; 384:1601-1612); (N Engl J Med 2021; 384:1589-1600).
  • See the Important Safety Information section below, including BOXED WARNING regarding increased risk of death, myocardial infarction, stroke, venous thromboembolism and thrombosis of vascular access.

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

Retrieved on: 
Thursday, March 28, 2024
CSL Vifor, Thrombosis, Myocardial infarction, Conference, Organization, Tablet, Caregiver, Anemia, Physician, CKD, Webcast, Patient, Coronary thrombosis, Stroke, AKBA, Death, Renal Support Network, Kidney disease, Nephrology, Kidney, Chronic kidney disease, Dialysis, Division, Safety, Stanford University, Food, Hypoxia, FDA, Erythropoietin, Pharmaceutical industry

CAMBRIDGE, Mass., March 27, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo is now approved in 37 countries.

Key Points: 
  • "At Akebia we are committed to kidney patients, a dedication that has driven our team to achieve this milestone.
  • We believe this commitment uniquely positions the company to execute a successful launch designed to drive toward a potential new oral standard of care for dialysis patients."
  • Approximately 500,000 adult patients in the U.S. on dialysis suffer from anemia due to CKD1, which may be associated with many adverse clinical outcomes.
  • Today, most CKD patients are treated for anemia with injectable erythropoiesis-stimulating agents mostly administered at dialysis centers.

WVU Medicine Joins Interwell Health Network to Bring Value-Based Kidney Care to West Virginia

Retrieved on: 
Tuesday, March 26, 2024
Health, Nephrology, Disease, Partnership, CKD, Patient, Mortality, Kidney disease, Chronic kidney disease, Vacuum, Machine learning, Medicine, Nursing, Social, Government, Physician

MORGANTOWN, W.Va., March 26, 2024 /PRNewswire/ -- WVU Medicine announced today that it has entered into an agreement with Interwell Health with the goal of improving the care of patients with kidney disease.

Key Points: 
  • MORGANTOWN, W.Va., March 26, 2024 /PRNewswire/ -- WVU Medicine announced today that it has entered into an agreement with Interwell Health with the goal of improving the care of patients with kidney disease.
  • WVU Medicine nephrologists will join the Interwell network and implement its population health approach to kidney care.
  • "We are thrilled to welcome this leading group of nephrologists at WVU Medicine to our network and to our mission to reimagine kidney care," Terry Ketchersid, M.D., M.B.A., senior vice president at Interwell Health, said.
  • Visit the Interwell Health physician page to learn more about how the company supports nephrology practices in the transition to value-based care.

CKD Leaders Network Publishes New Thought Piece in Journal of Clinical Medicine

Retrieved on: 
Thursday, March 21, 2024
Research, Disease, FACC, Conditional sentence, TKG, Data science, CKD, Medicine, Patient, Author, Mortality, Manuscript, University, ICMJE, MPH, Network, Chronic kidney disease, Eli Lilly and Company, Multimedia, Marketing, Boehringer Ingelheim, Pharmaceutical industry

NEW YORK, March 21, 2024 /PRNewswire/ -- In support of National Kidney Month, CKD Leaders Network , a Kinetix Group Network of Excellence dedicated to defining and spreading a best practice model for population health-driven chronic kidney disease (CKD) management, announced its new manuscript in the Journal of Clinical Medicine.

Key Points: 
  • NEW YORK, March 21, 2024 /PRNewswire/ -- In support of National Kidney Month, CKD Leaders Network , a Kinetix Group Network of Excellence dedicated to defining and spreading a best practice model for population health-driven chronic kidney disease (CKD) management, announced its new manuscript in the Journal of Clinical Medicine.
  • "At The Kinetix Group, we are committed to improving care delivery through collaboration and innovation," said Anna Thomas , executive vice president.
  • CKD affects approximately 37 million individuals in the United States.
  • To learn more about CKD Leaders Network initiatives, contact [email protected] .

Panoramic Health and The Kidney and Hypertension Center Join Forces to Elevate Kidney Care in Ohio

Retrieved on: 
Tuesday, March 19, 2024
Kidney, Health, Kidney disease, Growth, KHC, Partnership, CKD, Patient, Investment, Panorama, Chronic kidney disease, ESKD, Physician, Pharmaceutical industry

TEMPE, Ariz., March 19, 2024 /PRNewswire/ -- Panoramic Health, kidney care's leading integrated provider group, is proud to announce its strategic partnership with The Kidney and Hypertension Center (KHC), the largest independent nephrology practice in Cincinnati, Ohio. This represents the first Panoramic Health integrated provider group partnership in Ohio.

Key Points: 
  • This represents the first Panoramic Health integrated provider group partnership in Ohio.
  • The alliance between Panoramic Health and KHC underscores both entities' dedication to serving the full continuum for patients and physicians through complementary, integrated service lines.
  • "We are thrilled to partner with The Kidney and Hypertension Center in Cincinnati and mark this exciting entry into Ohio," said Dr. Tarek Elsawy, Chief Executive Officer at Panoramic Health.
  • In addition, by leveraging Panoramic Health's value-based care platform, KHC taps into care management that keeps the nephrologist at the center of care delivery, leading to improved patient outcomes.

CMUH(Taiwan) Using AI to Monitor Home Hemodialysis

Retrieved on: 
Monday, March 18, 2024
Ultrafiltration, Blood pressure, Osmotic pressure, Chronic kidney disease, Renal replacement therapy, Patient, Peritoneal dialysis, Home hemodialysis, Fatigue, AI, Quality of life, Dehydration, Water, Safety, Dialysis, Patient safety, Family, HHD, Work, Medical device

TAICHUNG, March 18, 2024 /PRNewswire/ -- Chronic Kidney Disease has become a new "national disease" in Taiwan, and the number of patients requiring hemodialysis is increasing. Traditionally, hemodialysis patients and accompanies require at least an hour spent on commuting, and that maybe even more time consuming for those who live in suburbs. Moreover, patients almost feel tired or fatigue and need rest half a day following hemodialysis. Since 2019 in Taiwan, China Medical University Hospital (CMUH) has initiated and implemented AI monitoring system for hemodialysis patients. The unique AI system receives the messages sent by the dialysis machine to keep track of any risk message with incorporated AI system, ensuring patient safety and collecting information for prescription adaptation. Accredited with CMUH's AI technology, those who require hemodialysis are not necessary to visit a healthcare facility for this routine. Dr. Huey-Liang Kuo, Director of Hemodialysis Center at CMUH, stated that patients have been heathier and safer to do hemodialysis at home.

Key Points: 
  • Since 2019 in Taiwan, China Medical University Hospital (CMUH) has initiated and implemented AI monitoring system for hemodialysis patients.
  • The unique AI system receives the messages sent by the dialysis machine to keep track of any risk message with incorporated AI system, ensuring patient safety and collecting information for prescription adaptation.
  • Accredited with CMUH's AI technology, those who require hemodialysis are not necessary to visit a healthcare facility for this routine.
  • Dr. Huey-Liang Kuo, Director of Hemodialysis Center at CMUH, stated that patients have been heathier and safer to do hemodialysis at home.

Dialysis Patient Citizens Applauds Passage of Legislation Securing Affordable Treatment for All Dialysis Patients in Indiana

Retrieved on: 
Thursday, March 14, 2024
DPC, Dialysis, Transplant, Kidney, Indiana Senate, Patient, ESRD, Dialysis Patient Citizens, Medicaid, Legislation, Indiana House of Representatives, Chronic kidney disease, Multimedia, Medicare, Representative, Person, Health insurance

WASHINGTON, March 14, 2024 /PRNewswire/ -- Dialysis Patient Citizens (DPC), the leading advocacy organization for dialysis patients nationwide, today released the following statement applauding the passage and enactment of SB 215 in Indiana.

Key Points: 
  • WASHINGTON, March 14, 2024 /PRNewswire/ -- Dialysis Patient Citizens (DPC), the leading advocacy organization for dialysis patients nationwide, today released the following statement applauding the passage and enactment of SB 215 in Indiana.
  • Dialysis Patient Citizens (DPC) applauds the passage and enactment of SB 215 in Indiana.
  • "We are grateful to see Indiana do right by dialysis patients and provide the patient choice and healthcare coverage that all Hossiers deserve," said DPC Board President Andrew Conkling.
  • This legislation offers affordable Medigap coverage to Medicare beneficiaries of all ages, granting all dialysis patients in Indiana access to affordable care.

BLACK AMERICANS AT HIGHER RISK FOR KIDNEY FAILURE AS BLACK HEALTH MATTERS, NATIONAL KIDNEY FOUNDATION FIGHT FOR EQUITY DURING NATIONAL KIDNEY MONTH

Retrieved on: 
Thursday, March 14, 2024
Health, BHM, NKF, Risk, Diabetes, Global health, Patient, National Kidney Foundation, EQUITY, ALL, Social media, Kidney failure, Kidney disease, Kidney, Chronic kidney disease, World Kidney Day, All, Pharmaceutical industry

NEW YORK, March 14, 2024 /PRNewswire/ -- Black Health Matters (BHM)– a leading nonprofit health advocacy organization that provides health and wellness information that is rooted in medical expertise to the Black community – is partnering with the National Kidney Foundation (NKF) to spread awareness about kidney equity during National Kidney Month. Observed in March each year, National Kidney Month aims to raise awareness about kidney health and chronic kidney disease. The month also includes World Kidney Day – a global health awareness day focusing on the importance of kidneys and the impact of kidney disease - which is observed March 14.

Key Points: 
  • Observed in March each year, National Kidney Month aims to raise awareness about kidney health and chronic kidney disease.
  • The month also includes World Kidney Day – a global health awareness day focusing on the importance of kidneys and the impact of kidney disease - which is observed March 14.
  • NKF continues to fight to get Kidney Equity for All - a commitment to make a difference in ALL kidney patients' lives!
  • "As an organization that spotlights health disparities and the importance of health in the Black community, kidney health has become a silent epidemic in our community," said Roslyn Young-Daniels, President, and Founder of Black Health Matters.

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 11, 2024
Chronic kidney disease, Dialysis, Anemia, Patient, Kidney disease, Akebia, Food, Vadadustat, AKBA, PDUFA

CAMBRIDGE, Mass., March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024.

Key Points: 
  • CAMBRIDGE, Mass., March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024.
  • Akebia will not host a conference call due to the proximity to the anticipated March 27, 2024 Prescription Drug User Fee Act (PDUFA) target action date for vadadustat, which is under review by the U.S. Food and Drug Administration as a treatment for anemia due to chronic kidney disease in adult patients on dialysis.

The American Diabetes Association and DaVita Strengthen Alliance to Tackle Chronic Disease Head-On

Retrieved on: 
Monday, March 11, 2024
Connect the dots, Health, Disability, Organization, Learning, Health equity, CKD, Risk, Education, Patient, Black, Dots, Death, American Diabetes Association, Chronic condition, RDS, Chronic kidney disease, DaVita Inc.

DENVER, March 11, 2024 /PRNewswire/ -- Today, The American Diabetes Association ® (ADA) and DaVita (NYSE: DVA), a leading provider of kidney care services, announced the expansion of a multi-year collaboration, focused on advancing chronic disease prevention, specifically addressing two of the most prevalent chronic conditions in the U.S. — diabetes and chronic kidney disease (CKD). The kick-off for this expanded effort coincides with National Kidney Month, a time when both organizations bolster efforts to increase kidney health awareness and education.

Key Points: 
  • Efforts to advance chronic disease prevention through enhanced education, awareness and support — kicking off during National Kidney Month
    DENVER, March 11, 2024 /PRNewswire/ -- Today, The American Diabetes Association ® (ADA) and DaVita (NYSE: DVA), a leading provider of kidney care services, announced the expansion of a multi-year collaboration, focused on advancing chronic disease prevention, specifically addressing two of the most prevalent chronic conditions in the U.S. — diabetes and chronic kidney disease (CKD).
  • Chronic disease is the leading cause of death and disability in the United States.
  • [1] More than 38 million Americans are living with diabetes, and approximately one in three American adults with diabetes has CKD.
  • On March 26, DaVita dietitians will join the ADA for a live cooking class featuring a tasty diabetes- and kidney-friendly meal.